For patients with idiopathic intracranial hypertension, GLP-1 RA treatment is associated with improved clinical outcomes.

Patients with idiopathic intracranial hypertension who use a GLP-1 receptor agonist are less likely to experience symptoms, require medications, or undergo surgery.

Those with clinical signs suggestive of idiopathic intracranial hypertension, such as papilledema or sixth nerve palsy, were excluded to focus on migraine without overt intracranial hypertension.

An Ozempic-like drug prescribed for diabetes has been found to reduce the frequency of debilitating migraine. Researchers say liraglutide, a GLP-1RA, might help migraine by reducing intracranial ...

Conclusion Papilledema is a typical manifestation of optic nerve head injury, particularly in bilateral cases. The direct cause of papilledema is increased intracranial pressure, and its root cause ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Background The River stent is the first stent specifically designed for intracranial venous sinuses. We report the 1-year results of the River trial, performed to obtain Humanitarian Device Exemption ...

Background Stenting of the intracranial venous sinuses is used as a treatment in certain cases of idiopathic intracranial hypertension (IIH). Interest in, and experience of, this technique is growing, ...

USA: Researchers have found in a new study that patients with idiopathic intracranial hypertension (IIH) treated with ...